A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-03245-x ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Andrea Kuemmerle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medicines for Malaria Venture, ICC - Block G, 3rd floor, 20, Route de Pré-Bois, PO Box 1826, 1215, Geneva, Switzerland. Hauptthemen laut MEDLINE: Atovaquone, Drug Combinations, Proguanil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medicines for Malaria Venture MMV.
Abstract (Originalsprache)
Atoguanil™ is a novel complex of atovaquone (ATV) and proguanil (PG) with enhanced ATV bioavailability compared to Malarone®. This pilot study assessed whether the relative bioavailability (F rel ) of ATV, PG, and the primary PG metabolite cycloguanil (CG) following a single oral dose in the fed state of Atoguanil was similar to Malarone despite a 50% lower ATV dose. This open-label, single-dose, randomized 2-period, 2-treatment, balanced crossover study was conducted between 17th November 2021 and 18th March 2022. Eligible participants (aged 18–55 years) were randomized (1:1) in period 1 to Atoguanil (ATV/PG 500/348 mg) or Malarone (ATV/PG hydrochloride 1000/400 mg) administered following a high-fat, high caloric meal. After a 24-day washout period, participants crossed treatment arms. For the doses tested, F rel was assumed similar if 90%CIs were between 80 and 125% for the geometric mean ratio of the least square mean differences for each exposure parameter. In 15 evaluable participants, F rel was similar for ATV C max (93.6% [90%CI 83.6, 104.9]) but not AUC 0-inf (77.8% [67.4, 89.8]), for PG AUC 0-inf (95.6% [92.1, 99.2]) but not C max (82.4% [75.8, 89.5]), and for both CG C max (100.8% [95.0, 107.0]) and AUC 0-inf (102.9% [98.4, 107.7]). Nine adverse events occurred; all were of mild severity and not considered treatment related. At the doses tested, ATV F rel was lower following Atoguanil versus Malarone based on AUC 0-inf , though when adjusted for dose F rel increased by 156%. Both drugs were well tolerated with no safety concerns. ClinicalTrials.gov: NCT04866602 (April 26th, 2021)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicines for Malaria Venture, ICC - Block G, 3rd floor, 20, Route de Pré-Bois, PO Box 1826, 1215, Geneva, Switzerland.
- Mangareva SRL, Kraainem, Belgium.
- ICON Clinical Research Germany GmbH, Langen, Germany.
- Richmond Pharmacology Ltd, London, UK.
- PharmaKinetic Ltd, Quorn, UK.
- IPCA Laboratories Limited, Mumbai, India.
Förderung
- Medicines for Malaria Venture MMV
Zitieren
APA
Kuemmerle, A., Gossen, D., Marx, M. W., Lorch, U., Szramowska, M., Kumar, A., Singh, D., Singh, S., Ramachandruni, H., Thankachen, B., Kore, S., Gaaloul, M. E., Borghini-Fuhrer, I., & Chalon, S. (2024). A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03245-x
Vancouver
Kuemmerle A, Gossen D, Marx MW, Lorch U, Szramowska M, Kumar A, et al. A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03245-x
BibTeX
@article{Kuemmerle2024,
author = {Kuemmerle, Andrea and Gossen, Denis and Marx, Michael W and Lorch, Ulrike and Szramowska, Maja and Kumar, Ashok and Singh, Dharmendra and Singh, Satinder and Ramachandruni, Hanu and Thankachen, Byju and Kore, Swapnil and Gaaloul, Myriam El and Borghini-Fuhrer, Isabelle and Chalon, Stephan},
title = {A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-03245-x}
}
EUVIMED